JP2018529648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529648A5 JP2018529648A5 JP2018506914A JP2018506914A JP2018529648A5 JP 2018529648 A5 JP2018529648 A5 JP 2018529648A5 JP 2018506914 A JP2018506914 A JP 2018506914A JP 2018506914 A JP2018506914 A JP 2018506914A JP 2018529648 A5 JP2018529648 A5 JP 2018529648A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- hydrogen
- alkyl
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carboxy, amino Chemical group 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 150000002431 hydrogen Chemical group 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 108010016626 Dipeptides Proteins 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 230000003920 cognitive function Effects 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 6
- 0 *C(*)(C(C(*)(*)C1(*)N)N*)C1S(O)(=O)=O Chemical compound *C(*)(C(C(*)(*)C1(*)N)N*)C1S(O)(=O)=O 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203256P | 2015-08-10 | 2015-08-10 | |
| US62/203,256 | 2015-08-10 | ||
| PCT/US2016/046336 WO2017027582A1 (en) | 2015-08-10 | 2016-08-10 | Compositions and methods for treating and preventing neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529648A JP2018529648A (ja) | 2018-10-11 |
| JP2018529648A5 true JP2018529648A5 (enExample) | 2019-09-26 |
| JP6928385B2 JP6928385B2 (ja) | 2021-09-01 |
Family
ID=57983633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506914A Active JP6928385B2 (ja) | 2015-08-10 | 2016-08-10 | 神経変性疾患を治療および予防するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10590070B2 (enExample) |
| EP (1) | EP3334710B1 (enExample) |
| JP (1) | JP6928385B2 (enExample) |
| KR (1) | KR102657460B1 (enExample) |
| CN (1) | CN108026049B (enExample) |
| AU (1) | AU2016304862B2 (enExample) |
| EA (1) | EA035650B1 (enExample) |
| ES (1) | ES2965867T3 (enExample) |
| IL (1) | IL257332B (enExample) |
| MX (1) | MX380290B (enExample) |
| WO (1) | WO2017027582A1 (enExample) |
| ZA (1) | ZA201800831B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035650B1 (ru) | 2015-08-10 | 2020-07-21 | Алжеон, Инк. | Композиции и способы лечения и предотвращения нейродегенеративных расстройств |
| CN114805211B (zh) | 2017-03-21 | 2024-08-23 | 润佳（苏州）医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Ｐｒｍｔ５を標的にする化合物 |
| PH12021553196A1 (en) * | 2019-06-17 | 2022-11-07 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| US20250345298A1 (en) | 2022-04-28 | 2025-11-13 | Alzheon, Inc. | Apoe4 correctors and methods of use |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0407701A3 (en) * | 1989-05-15 | 1992-04-22 | Fujisawa Pharmaceutical Co., Ltd. | Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| PT1040094E (pt) * | 1997-12-17 | 2009-06-03 | Biocryst Pharm Inc | Compostos de ciclopentano e de ciclopenteno substituídos úteis como inibidores da neuraminidase |
| CA2369997C (en) * | 1999-04-28 | 2009-11-17 | Queen's University At Kingston | Compositions and methods for treating amyloidosis |
| KR20050101537A (ko) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| ZA200509647B (en) * | 2003-06-23 | 2008-04-30 | Neurochem Int Ltd | Methods and compositions for treating amyloid-related diseases |
| AU2004249529A1 (en) * | 2003-06-23 | 2004-12-29 | Bellus Health (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| SI2089417T1 (sl) * | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
| US20090004140A1 (en) * | 2007-06-26 | 2009-01-01 | Yao-Ling Qiu | 4-substituted pyrrolidine as anti-infectives |
| KR101173677B1 (ko) * | 2009-12-11 | 2012-08-13 | 한국과학기술연구원 | Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EA035650B1 (ru) | 2015-08-10 | 2020-07-21 | Алжеон, Инк. | Композиции и способы лечения и предотвращения нейродегенеративных расстройств |
-
2016
- 2016-08-10 EA EA201890460A patent/EA035650B1/ru unknown
- 2016-08-10 WO PCT/US2016/046336 patent/WO2017027582A1/en not_active Ceased
- 2016-08-10 MX MX2018001592A patent/MX380290B/es unknown
- 2016-08-10 EP EP16835830.7A patent/EP3334710B1/en active Active
- 2016-08-10 AU AU2016304862A patent/AU2016304862B2/en active Active
- 2016-08-10 CN CN201680053914.1A patent/CN108026049B/zh active Active
- 2016-08-10 JP JP2018506914A patent/JP6928385B2/ja active Active
- 2016-08-10 KR KR1020187006588A patent/KR102657460B1/ko active Active
- 2016-08-10 US US15/751,547 patent/US10590070B2/en active Active
- 2016-08-10 ES ES16835830T patent/ES2965867T3/es active Active
-
2018
- 2018-02-04 IL IL257332A patent/IL257332B/en active IP Right Grant
- 2018-02-08 ZA ZA2018/00831A patent/ZA201800831B/en unknown
-
2020
- 2020-03-03 US US16/807,747 patent/US11053192B2/en active Active
-
2022
- 2022-02-16 US US17/673,269 patent/US12187668B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019094345A5 (enExample) | ||
| WO2021012049A8 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
| JP2009504763A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2013540114A5 (enExample) | ||
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| JP2012517428A5 (enExample) | ||
| WO2022029138A1 (en) | Low molecular weight protein degraders and their applications | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| GEP20125621B (en) | 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor | |
| JP2008501637A5 (enExample) | ||
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| PE20110829A1 (es) | Derivados aminoester de alcaloides y composicion medicinal de los mismos | |
| JP2004517843A5 (enExample) | ||
| RU2010129929A (ru) | Производные 5-оксо-3-пирролидинкарбоксамида в качестве модуляторов р2х7 | |
| JP2013542267A5 (enExample) | ||
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| JP2018529690A5 (enExample) | ||
| RU2007147344A (ru) | Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний | |
| JP2005526794A5 (ja) | ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用 | |
| CA2507505A1 (en) | N-arylsulfonyl-3-aminoalkoxyindoles | |
| JP2018529648A (ja) | 神経変性疾患を治療および予防するための組成物および方法 | |
| JP2023513655A5 (enExample) | ||
| JP2010535204A5 (enExample) |